Mowel (Mycophenolate Mofetil)

Mycophenolate mofetil is converted to mycophenolic acid, which blocks the enzyme inosine monophosphate dehydrogenase. This inhibition prevents the synthesis of guanosine nucleotides that lymphocytes need for proliferation, thereby selectively reducing the activity of B and T cells and dampening the immune response.

The specific dose of Mowel is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other clinical factors. Healthcare professionals tailor the regimen to achieve optimal immunosuppression while minimizing adverse effects.

Mowel is classified as pregnancy category X because it can cause fetal harm and is contraindicated in pregnancy. It is also not recommended for breastfeeding mothers, as the drug may be excreted in breast milk and affect the infant.

To request Mowel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism focused on nucleotide synthesis inhibition, which may result in a distinct side‑effect profile. It is often used in combination with other agents to achieve synergistic immunosuppression while allowing lower doses of each drug.

Mowel should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keeping the product in a dry, well‑ventilated area helps maintain its stability and potency throughout its shelf life.

Mowel is taken orally, usually as a tablet, and should be swallowed whole with water. The exact dosing schedule—such as once or twice daily—depends on the prescribing clinician’s instructions and the therapeutic indication.

The most serious risks include bone‑marrow suppression leading to severe leukopenia or anemia, opportunistic infections, potential development of malignancies, hepatic injury, and teratogenic effects that can cause fetal abnormalities. Patients should be monitored regularly for these complications.

Mowel is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate mofetil or any excipients, and patients with severe, uncontrolled infections. Caution is also advised for those with significant renal or hepatic impairment, where dose adjustments may be required.